Difucosyllactose (DFL), or lactodifucotetraose, is a prominent bisfucosylated human milk oligosaccharide (HMO) that plays a critical role in neonatal health by providing protection against enteric pathogens and supporting a healthy gut microbiome. Structurally characterized by the presence of both ɑ-1,2 and ɑ-1,3 linkages, DFL is a complex carbohydrate that is difficult to synthesize through traditional chemical methods due to the requirement for high regioselectivity. CD BioGlyco offers a specialized DFL production service powered by our state-of-the-art synthetic glycobiology platform. We utilize multidimensional metabolic engineering to transform microbial hosts into efficient cell factories capable of high-titer biosynthesis. Our approach ensures the delivery of high-purity, human-identical DFL that meets the rigorous demands of the pharmaceutical, nutraceutical, and infant nutrition research.
Core Technologies
We leverage integrated synthetic biology strategies to overcome metabolic bottlenecks:
Matched Fucosyltransferase Engineering
We utilize specialized pairs of ɑ-1,2-fucosyltransferases and ɑ-1,3-fucosyltransferases (e.g., SAMT and Fut3Bc) that are optimized for synergistic catalytic activity.
De Novo GDP-L-fucose Pathway Enhancement
By overexpressing key gene clusters (manB, manC, gmd, and wcaG) under constitutive promoters, we maintain a saturating pool of donor sugars for continuous glycosylation.
Protein Evolution via AlphaFold 3
We employ structural modeling to generate beneficial mutants, such as Fut3Bc(F24Y), which exhibit significantly enhanced catalytic efficiency compared to wild-type enzymes.
Plasmid-Free Genomic Integration
To ensure industrial stability and antibiotic-free production, we integrate multicopy biosynthetic modules directly into the host genome (e.g., E. coli MG1655), eliminating plasmid loss issues.
Precision Glycobiology for a Healthier Generation: Scaling the Future of Bio-Identical HMOs.
At CD BioGlyco, our DFL production service is designed to be a comprehensive solution for organizations seeking reliable access to bisfucosylated glycans. Our service scope encompasses the entire value chain of synthetic glycobiology, starting from custom strain engineering, where we develop proprietary microbial factories tailored to your specific feedstock requirements. We provide process development and optimization, ensuring that the biosynthesis of DFL is both scalable and economically viable for commercial applications.
In addition to large-scale production, our scope includes advanced structural characterization of complex glycans. We offer analytical standard provision, supplying high-purity DFL for use in glycomics and clinical research. Our team also specializes in co-production strategies, where we can engineer strains to produce specific ratios of 2'-FL and DFL, mimicking the natural composition of human milk. By integrating genomic engineering with high-throughput screening, CD BioGlyco ensures that our clients receive a product that is not only chemically identical to natural HMOs but also produced with the highest standards of sustainability and safety.
Workflow
1. Pathway Design & Simulation
We employ advanced computational systems biology tools to design and model the optimal metabolic pathway for DFL (difucosyllactose) biosynthesis. This involves the use of constraint-based genome-scale metabolic models (GEMs) and in silico flux balance analysis (FBA) to simulate carbon flux distribution. The analysis identifies critical nodes and competing pathways that drain essential precursors, such as GDP-L-fucose and lactose. Based on these simulations, we pinpoint precise gene knockout or knockdown targets (e.g., lon protease to stabilize pathway enzymes, or zwf in the pentose phosphate pathway to redirect glucose flux) to eliminate metabolic bottlenecks, minimize byproduct formation, and rationally maximize the intracellular availability of building blocks required for high-yield DFL synthesis.
2. Multimodule Strain Construction
The biosynthetic pathway is constructed in a modular fashion and stably integrated into the host genome for long-term stability. We utilize advanced genome editing technologies, such as CRISPR/Cas9 for precise, marker-free integration or lambda-Red recombinase for efficient homologous recombination in E. coli. The "donor module," containing the cascade of enzymes for de novo GDP-L-fucose synthesis, and the "transferase module," harboring one or more specific fucosyltransferases (capable of sequentially adding fucose to lactose), are assembled and inserted into predetermined neutral genomic loci. This approach ensures robust, plasmid-free expression and provides a stable foundation for subsequent optimization.
3. Iteration & Optimization
Strain performance is enhanced through an iterative design-build-test-learn (DBTL) cycle. We refine the initial construct by systematically reprogramming the expression of individual modules. This involves tuning the copy number of key glycosyltransferase genes through genomic integration at loci with different transcriptional activities or by employing chromosomal promoter libraries. The goal is to achieve a perfectly balanced enzyme stoichiometry that drives the sequential fucosylation reactions efficiently, thereby maximizing the molar conversion of the starting substrate (lactose) into the desired DFL product while minimizing the accumulation of intermediate mono-fucosylated sugars (like 2′-FL or 3′-FL).
4. High-Density Precision Fermentation
The final engineered strain is transitioned to a high-density fed-batch fermentation process in precisely controlled bioreactors. We develop and implement sophisticated feeding strategies that independently control the supply of the primary carbon source (e.g., glucose or glycerol for biomass and energy) and the acceptor substrate (lactose). Parameters such as feeding rates, induction timing, dissolved oxygen, and pH are meticulously optimized in real-time to maintain the cells in a productive metabolic state, avoid substrate inhibition or repression, and achieve the highest possible volumetric titer and yield of DFL.
5. Downstream Purification
Recovery and purification of DFL from the fermentation broth are achieved through a proprietary, sequential downstream process. Initial steps include centrifugation and microfiltration for cell harvest and clarification. This is followed by ultrafiltration/diafiltration to remove host cell proteins and DNA. The core purification employs high-resolution chromatographic techniques (e.g., specific adsorption chromatography or size-exclusion chromatography) designed to selectively isolate DFL from structurally similar molecules, including residual lactose and mono-fucosylated isomers (e.g., 2′-FL). The process is designed to be scalable and robust, delivering a consistently pure product stream.
6. Analytical Validation
The identity, purity, and structure of every DFL batch are confirmed using a suite of orthogonal analytical methods. High-performance liquid chromatography (HPLC) with appropriate detectors quantifies purity and assesses the absence of major impurities. Liquid chromatography-mass spectrometry (LC-MS) provides precise molecular weight confirmation and detects trace contaminants. Finally, proton nuclear magnetic resonance (1H-NMR) spectroscopy delivers definitive structural proof by characterizing the unique anomeric proton signatures of the α-1,2 and/or α-1,3 linkages in DFL, confirming its isomeric identity and ensuring a final chemical purity exceeding 98%.
Publication Data
Journal: EFSA Journal
DOI: 10.2903/j.efsa.2019.5717
IF: 3.3
Published: 2019
Results: This EFSA scientific opinion assesses the safety of 2′-FL produced by a genetically modified E. coli K-12 strain as a novel food ingredient. Crucially, the evaluation includes difucosyllactose DFL as a minor impurity (0.5–1.5% w/w) present in the 2′-FL product. The EFSA Panel on Nutrition, Novel Foods and food allergens (NDA) reviewed toxicological, compositional, and allergenicity data for both compounds. DFL, like 2′-FL, is a natural human milk oligosaccharide. The Panel concluded that DFL's presence in 2′-FL preparations does not raise safety concerns for the intended target populations (infants, young children, and adults). The assessment established an Acceptable Daily Intake (ADI) for total added HMOs, including DFL, based on the no-observed-adverse-effect level (NOAEL) of 6,000 mg/kg bw/day from a 90-day rat study. Manufacturing controls ensure consistent impurity profiles.
Application
Gut-Lung Axis Research
Scientists utilize our high-purity DFL to investigate how bisfucosylated glycans modulate systemic immune responses and protect against respiratory tract infections in early childhood.
Pathogen Anti-Adhesion Assays
DFL serves as a soluble decoy for pathogens like Norovirus and Campylobacter jejuni, and our high-purity material is essential for establishing effective dosage levels in anti-infective studies.
Neurodevelopment and Memory
As a source of fucose, DFL supports the sialylation and fucosylation processes in the brain, which are critical for synaptogenesis and long-term cognitive health during development.
Metabolic Health Research
Incorporated into dietary products to evaluate its effect on lipid metabolism and insulin sensitivity by altering the metabolic output of the intestinal microbiota.
Advantages
Industrial Plasmid-Free Stability
Our strains are engineered with genomic integrations, ensuring stable DFL production over multiple generations without the need for expensive and regulated antibiotics.
Regioselective Precision
Our engineered fucosyltransferases ensure perfect ɑ-1,2 and ɑ-1,3 linkages, eliminating the formation of structural isomers that compromise biological activity.
Optimized Flux Control
By deleting competing pathways (e.g., ΔlacZ, ΔwcaJ), we redirect 100% of the lactose flux toward DFL synthesis, achieving titers exceeding 15-20 g/L in lab-scale systems.
AlphaFold-Enhanced Enzymes
We utilize AI-driven protein engineering to modify enzyme binding pockets, resulting in a significant increase in catalytic speed and product purity.
Frequently Asked Questions
Customer Review
"CD BioGlyco provided us with DFL of unparalleled purity. Their ability to deliver structural data alongside the product was instrumental in our recent publication."
– Dr. S.T., Department Head, Pediatric Nutrition
"The stability of the plasmid-free strains developed by CD BioGlyco is impressive. Their production titers exceeded our expectations, significantly lowering our project costs."
– Manager R.W., R&D, Bio-Pharmaceuticals
"We have tried several DFL sources, but CD BioGlyco's material is the most consistent. Their expertise in ɑ-1,3-fucosyltransferase engineering is evident in the product quality."
– Dr. M.L., Senior Researcher, Microbiome Studies
Associated Services
Ascorbyl Glucoside Production Service
High-stability vitamin C derivatives for premium cosmeceuticals.
Acetyl Chitosamine Production Service
Specialized amino-sugar synthesis for joint health and skincare.
Trehalose Production Service
High-purity disaccharide production for protein stabilization and cryopreservation.
CD BioGlyco stands at the forefront of the HMO revolution, providing industry-leading DFL production services. Through our mastery of Synthetic Glycobiology and multidimensional engineering, we offer a sustainable and high-purity supply of this essential bisfucosylated glycan. Our commitment to scientific excellence and regulatory compliance makes us the partner of choice for organizations looking to pioneer the next generation of humanized nutritional and therapeutic products. To learn more about our DFL production capabilities or to request a specialized project consultation, contact us. Our team of expert glycobiologists is ready to help you achieve your production goals.
Reference
EFSA Panel on Nutrition.; et al. Safety of 2'-fucosyllactose/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2019, 17(6): e05717. (Open Access)
For research use only. Not intended for any clinical use.
